Literature DB >> 29687052

Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures.

Solomon L Woldu1, Ryan C Hutchinson1, Nirmish Singla1, Brad Hornberger1, Claus G Roehrborn1, Yair Lotan1.   

Abstract

INTRODUCTION: A number of strategies have been attempted to minimize infection risk following transrectal prostate procedures (TRPXs). We report our prospective efforts at augmenting our prophylaxis strategy over time.
METHODS: Since 2010, we prospectively monitor post-TRPX infections and changed our prophylaxis regimen twice in an effort to respond to increases in infectious complications. In 2011 we added a single-dose of intramuscular (IM) aminoglycoside to our prophylaxis regimen of fluoroquinolones (FQ) or trimethoprim-sulfamethoxazole. In 2015 we began performing formalin needle-tip disinfection before each biopsy and screening high-risk patients for antibiotic resistance using rectal swab cultures (targeted prophylaxis). We report our rates of infections and antibiotic resistance patterns over this period.
RESULTS: From 2010-2016, we performed 2398 TRPXs; overall, there were 41 cases (1.7%) of infection-related hospitalization, however the rate differed significantly over the study period. The infection-related hospitalization rate declined from 3.8 to 1.1% in the first 3 years following the addition of IM aminoglycoside (2011-2013) - a decrease of 69%. In 2014 our infection rate increased to 2.6% prompting initiation of protocol #3 wherein the addition of target prophylaxis and formalin needle-tip disinfection identified a 29.8% FQ-resistance rate and resulted in another decline in our infection rate to 1.2% - a decrease of 53%.
CONCLUSIONS: While the initial addition of IM aminoglycoside appeared to be effective in decreasing post-procedure infections, further augmentation of our prophylaxis regimen through rectal swab screening of high-risk patients and formalin needle-tip disinfection led to an additional decline in rates of infection-related hospitalizations.

Entities:  

Keywords:  antibiotic resistance; cost; fiducial marker; infection; prostate biopsy; rectal swab

Year:  2017        PMID: 29687052      PMCID: PMC5909829          DOI: 10.1016/j.urpr.2017.03.002

Source DB:  PubMed          Journal:  Urol Pract        ISSN: 2352-0779


  27 in total

1.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

2.  Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures.

Authors:  Joel H Hillelsohn; Brian Duty; Michael L Blute; Zhamshid Okhunov; Mahyar Kashan; Robert Moldwin; Richard N Ashley
Journal:  Can J Urol       Date:  2012-12       Impact factor: 1.344

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  The problem of infection after prostatic biopsy: the case for the transperineal approach.

Authors:  P M Thompson; J P Pryor; J P Williams; D E Eyers; C Dulake; M F Scully; V V Kakkar
Journal:  Br J Urol       Date:  1982-12

5.  Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.

Authors:  Robert K Nam; Refik Saskin; Yuna Lee; Ying Liu; Calvin Law; Laurence H Klotz; D Andrew Loblaw; John Trachtenberg; Aleksandra Stanimirovic; Andrew E Simor; Arun Seth; David R Urbach; Steven A Narod
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

Review 6.  Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations.

Authors:  A Erb; T Stürmer; R Marre; H Brenner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

7.  Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy.

Authors:  Karl-Johan Lundström; Linda Drevin; Stefan Carlsson; Hans Garmo; Stacy Loeb; Pär Stattin; Anna Bill-Axelson
Journal:  J Urol       Date:  2014-05-09       Impact factor: 7.450

8.  A Prospective Randomized Trial Comparing a Combined Regimen of Amikacin and Levofloxacin to Levofloxacin Alone as Prophylaxis in Transrectal Prostate Needle Biopsy.

Authors:  Yu Miyazaki; Shusuke Akamatsu; Sojun Kanamaru; Yuki Kamiyama; Atsushi Sengiku; Ryo Iguchi; Takeshi Sano; Akira Takahashi; Masaaki Ito; Jun Takenawa; Noriyuki Ito; Keiji Ogura
Journal:  Urol J       Date:  2016-03-05       Impact factor: 1.510

9.  A single 80 mg intravenous gentamicin dose prior to prostate needle biopsy does not reduce procedural infectious complications.

Authors:  Jay D Raman; Chris Rjepaj; Christopher Otteni
Journal:  Cent European J Urol       Date:  2015-04-30

10.  Risk factors for infection following prostate biopsy - a case control study.

Authors:  Elliot Anderson; Olivia Leahy; Allen C Cheng; Jeremy Grummet
Journal:  BMC Infect Dis       Date:  2015-12-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.